Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.

@article{Bonini2018PhaseIR,
  title={Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.},
  author={Stefano Bonini and Alessandro Lambiase and Pathapati Rama and Francesco Dr. Sinigaglia and Marcello Allegretti and Wendy Chao and Flavio Mantelli},
  journal={Ophthalmology},
  year={2018},
  volume={125 9},
  pages={
          1332-1343
        }
}
PURPOSE To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from impaired corneal innervation. DESIGN Phase II multicenter, randomized, double-masked, vehicle-controlled trial. PARTICIPANTS Patients with stage 2 (moderate) or stage 3 (severe) NK in 1 eye. METHODS The REPARO phase II study assessed safety and efficacy in 156 patients randomized… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 9 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Neurotrophic keratitis

  • BH Chang, EB Groos
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…